Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.42 |
| ▸ | HTR2A | P28223 | 8/20 | 0.42 |
| ▸ | HTR2B | P41595 | 7/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2078547 | 0.83 | HTR2C (0.56) | HTR2CHTR2AHTR2BHTR1ASLC6A2 | |
| SCHEMBL2078552 | 0.83 | HTR2C (0.56) | HTR2CHTR2AHTR2BHTR1ASLC6A2 | |
| SCHEMBL27010611 | 0.79 | HTR2C (0.37) | HTR2CHTR2AHTR2BDRD2DRD1 | |
| SCHEMBL30309386 | 0.79 | DRD2 (0.36) | HTR2CHTR2AHTR2BDRD2DRD1 | |
| SCHEMBL5187232 | 0.79 | DRD2 (0.39) | HTR2CHTR2AHTR2BDRD2DRD1 | |
| SCHEMBL12891520 | 0.73 | CYP19A1 (0.51) | HTR2CHTR2AHTR2BDRD2DRD1 | |
| SCHEMBL12891517 | 0.73 | CYP19A1 (0.51) | HTR2CHTR2AHTR2BDRD2DRD1 | |
| SCHEMBL8360110 | 0.73 | CYP19A1 (0.51) | HTR2CHTR2AHTR2BDRD2DRD1 | |
| SCHEMBL10054051 | 0.72 | CYP19A1 (0.43) | HTR2CHTR2AHTR2BDRD2DRD1 | |
| SCHEMBL30640672 | 0.72 | CYP19A1 (0.43) | HTR2CHTR2AHTR2BDRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2015130842-A9 | ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | HTR2C 3544/4885HTR2A 3868/4885HTR2B 4767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.